In non-small-cell lung cancer (NSCLC), CKI combined with platinum-based chemotherapy improved quality of life, disease control rates, and overall response rates compared with chemotherapy alone [164]. The gene discussed is CHKA; the disease is non-small cell lung carcinoma.